About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety and Efficacy of Low-Fluence PRP for PDR | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNANCT01737957

Safety and Efficacy of Low-Fluence PRP for PDR

To determine the safety and efficacy of a single session of low-fluence panretinal photocoagulation when compared to full-fluence PRP. Hypothesis: a single-session of low-fluence PRP will be safe rega...

Lead sponsor: Asociación para Evitar la Ceguera en México•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Asociación para Evitar la Ceguera en México

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Type 1 or type 2 diabetics
•Proliferative diabetic retinopathy

Exclusion Criteria

•Previous treatment with PRP
•Media opacities
•Previous treatment for macular edema (LASER or intravitreal injections)
•Recent (less than 6 months) ophthalmic surgery
•Only eyes
•Intra-retinal or sub-retinal fluid with foveal involvement
•Chronic renal failure
•History of liver or pancreatic transplant

Related studies

RECRUITINGPhase 2

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), and more

Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy

NCT06713720 · Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, and more

Enrolling By InvitationPhase 3

Intravitreal and Intracameral DEX in NPDR

NCT06951087 · Non-Proliferative Diabetic Retinopathy

Active Not RecruitingPhase 2

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284 · Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

Genetic Markers and Proliferative Diabetic Retinopathy

NCT02879422 · Proliferative Diabetic Retinopathy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 30, 2024Terms

Trial snapshot

StatusTERMINATED

PhaseNA

Enrollment60

Start dateNov 2012

Last updatedMay 30, 2024

Condition

Proliferative Diabetic Retinopathy

Locations shown

Asociación Para Evitar la Ceguera en México

Mexico City, Mexico City

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2024Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions